Vorasidenib is indicated for the treatment of people aged twelve years of age and older with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or isocitrate dehydrogenase-2 mutation, following surgery including biopsy, sub-total resection, or gross total resection. Vorasidenib was approved for medical use in the United States in August 2024. It is the first approval by the US Food and Drug Administration (FDA) of a systemic therapy for people with grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 or isocitrate dehydrogenase-2 mutation.
\nThe most common adverse reactions include fatigue, headache, increased risk of COVID-19 infection, musculoskeletal pain, diarrhea, nausea, and seizures.<\/p>\n
It may be accessed in India through a named-patient import process<\/strong>\u00a0with a valid doctor\u2019s prescription, and\u00a0Indian Pharma Network (IPN), New Delhi, assists with compliant sourcing<\/strong>\u00a0and delivery of specialty medicines subject to regulatory approvals.<\/p>\n Indian Pharma Network (IPN), based in New Delhi, helps patients and healthcare providers with the sourcing and import coordination of specialty medicines in compliance with applicable Indian regulations.<\/strong>\u00a0Availability, import eligibility, pricing, and delivery timelines may vary and are subject to regulatory approvals and documentation requirements.<\/p>\n IPN having representation in<\/strong>\u00a0Delhi, Gurugram, Mumbai, Bengaluru, Kolkata, Chennai, Pune, Ahmedabad, Hyderabad, Chandigarh, Jaipur, and Lucknow.<\/p>\n Named-patient import facilitator contact details<\/strong> Patients are advised to independently verify the credentials, licensing, and regulatory compliance of any facilitator before proceeding.<\/em><\/p>\n NEWS \/ UPDATES<\/p>\n Note:<\/strong><\/em> <\/p>\n","protected":false},"excerpt":{"rendered":" It is an anti-cancer medication used for the treatment of certain forms of glioma. Vorasidenib is a dual mutant isocitrate dehydrogenase 1 and isocitrate dehydrogenase 2 (mIDH1\/2) inhibitor.<\/p>\nHow to get VORANIGO tablets delivered in India?<\/h4>\n
Who can help source VORANIGO tablets in India legally?<\/h4>\n
\nCompany Name:<\/strong>\u00a0Indian Pharma Network (IPN)
\nAddress:<\/strong>\u00a060\/4 1st Floor, T&T Building, Indian Oil Complex, Yusuf Sarai, Delhi 110016
\nFor sourcing and import coordination of specialty medicines, contact:<\/strong>
\nMr. Tarun:<\/strong>\u00a0+91 9891 296 838
\nMr. Neeraj:<\/strong>\u00a0+91 9811 747 774
\nEmail:\u00a0info@indianpharmanetwork.co.in<\/a><\/strong><\/p>\n\n
\nWe are the facilitator, group of highly qualified healthcare professionals, provide solutions on how to get access of anti cancer medicines not available in India. On the basis of permission in Form 12B (Import permit) from From Ministry of Health, Government of India, IPN, New Delhi procure drugs on behalf of patient.\u00a0Indian Pharma Network (IPN) serves as a legitimate consultant and facilitator situated in New Delhi, India<\/a>. With over two decades of industry experience, IPN offers extensive coverage across India.<\/em><\/p>\nVORANIGO (vorasidenib) is used to treat certain forms of glioma.<\/h2>\n
\n\n
\n Brand Name:<\/strong><\/td>\n VORANIGO<\/td>\n<\/tr>\n \n Generic Name:<\/strong><\/td>\n vorasidenib<\/td>\n<\/tr>\n \n Strength:<\/strong><\/td>\n Tablets: 10 mg and 40 mg.<\/td>\n<\/tr>\n \n Manufacturer:<\/strong><\/td>\n Servier Pharmaceuticals<\/td>\n<\/tr>\n \n Approved By:<\/strong><\/td>\n EMA, USFDA<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n